At the time of writing, Cytokinetics Inc [CYTK] stock is trading at $57.39, up 3.35%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CYTK shares have gain 2.03% over the last week, with a monthly amount drifted -2.75%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on August 13, 2024, when Goldman downgraded its rating to a Neutral and also revised its price target to $60 from $85. Previously, UBS downgraded its rating to Neutral on January 24, 2024, and elevated its price target to $92. On January 05, 2024, downgrade downgraded it’s rating to Equal-Weight and revised its price target to $90 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $50 on November 09, 2023. B. Riley Securities initiated its recommendation with a Buy and recommended $66 as its price target on November 07, 2023. SVB Securities started tracking with a Outperform rating for this stock on August 15, 2023, and assigned it a price target of $58. In a note dated February 17, 2023, BofA Securities initiated an Neutral rating and provided a target price of $49 on this stock.
For the past year, the stock price of Cytokinetics Inc fluctuated between $25.98 and $110.25. Currently, Wall Street analysts expect the stock to reach $82.67 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $57.39 at the most recent close of the market. An investor can expect a potential return of 44.05% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
According to Cytokinetics Inc [NASDAQ:CYTK], the company’s sales were 3.13M for trailing twelve months, which represents an -71.28% plunge. Gross Profit Margin for this corporation currently stands at -28.87% with Operating Profit Margin at -161.48%, Pretax Profit Margin comes in at -173.99%, and Net Profit Margin reading is -173.99%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is 1.96 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of6.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.51 points at the first support level, and at 53.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 58.98, and for the 2nd resistance point, it is at 60.56.
Ratios To Look Out For
It is important to note that Cytokinetics Inc [NASDAQ:CYTK] has a current ratio of 10.39. In addition, the Quick Ratio stands at 10.39 and the Cash Ratio stands at 1.85. Considering the valuation of this stock, the price to sales ratio is 2157.35, the price to book ratio is 62.14.
Transactions by insiders
Recent insider trading involved B LYNNE PARSHALL, Director, that happened on Aug 26 ’24 when 5000.0 shares were purchased. Director, PARSHALL B LYNNE completed a deal on Aug 26 ’24 to sell 5000.0 shares. Meanwhile, EVP Research & Development Malik Fady Ibraham sold 7300.0 shares on Aug 20 ’24.
